Acute Myocardial Infarction Market (2026–2030): Developments and Opportunities

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Acute Myocardial Infarction Market Be By 2030 Compared To Its 2026 Market Size?

The acute myocardial infarction market size has shown considerable expansion in recent years. It is forecast to grow from $1.56 billion in 2025 to $1.65 billion in 2026, at a compound annual growth rate (CAGR) of 6.0%. The past growth in this market can be attributed to several factors, including the increasing prevalence of coronary artery disease, a rise in hospitals and specialty cardiac centers, wider adoption of electrocardiogram and imaging techniques, growing awareness of acute MI symptoms, and the expansion of cardiac research initiatives.

The acute myocardial infarction market is projected to experience significant growth in the coming years, with its size anticipated to reach $2.06 billion by 2030 at a compound annual growth rate (CAGR) of 5.7%. This expansion during the forecast period is primarily attributed to the development of novel thrombolytic agents, the increasing adoption of minimally invasive procedures, the integration of advanced imaging technologies, the emergence of personalized cardiology treatments, and the incorporation of AI and big data in cardiac care. Furthermore, key trends in this period include the wider acceptance of percutaneous coronary intervention (PCI) procedures, the rising utilization of advanced cardiac biomarkers for early diagnosis, a heightened focus on less invasive cardiac treatments, the expansion of telecardiology and remote patient monitoring services, and enhanced awareness and prevention programs for acute MI.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/acute-myocardial-infarction-global-market-report

Which Strong Drivers Are Impacting The Acute Myocardial Infarction Market Growth?

A projected increase in hypertension cases is anticipated to drive the expansion of the acute myocardial infarction market moving ahead. Hypertension, defined by consistently elevated blood pressure, elevates the likelihood of developing heart disease, strokes, and various other health issues. The number of hypertension cases is growing, primarily attributed to the widespread adoption of sedentary lifestyles, stemming from factors like desk-bound occupations, extended periods of screen use, and insufficient physical activity. Hypertension contributes to acute myocardial infarction through mechanisms such as arterial damage, accelerated plaque accumulation, and an elevated propensity for blood clot formation that can obstruct coronary arteries. For example, in September 2025, the World Health Organization, an intergovernmental organization based in Switzerland, reported that in 2024, an estimated 1.4 billion adults globally, aged 30–79, were affected by hypertension, making up about one-third of that age group’s population. Consequently, the escalating incidence of hypertension is propelling the expansion of the acute myocardial infarction market.

How Are Segments Identified Within The Acute Myocardial Infarction Market Segment Framework?

The acute myocardial infarction market covered in this report is segmented –

1) By Type: ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI)

2) By Treatment Type: Thrombolytic Therapy, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG), Medications

3) By Diagnosis Method: Electrocardiogram, Cardiac Biomarkers, Echocardiography, Coronary Angiography, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan

4) By Route Of Administration: Oral Route, Intravenous (IV) Route, Subcutaneous Route, Transdermal Route, Sublingual Route

5) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Specialty Cardiac Centers, Research Institutes

Subsegments:

1) By ST-Elevation Myocardial Infarction (STEMI): Anterior ST-Elevation Myocardial Infarction (STEMI), Inferior ST-Elevation Myocardial Infarction (STEMI), Posterior ST-Elevation Myocardial Infarction (STEMI), Lateral ST-Elevation Myocardial Infarction (STEMI), Right Ventricular ST-Elevation Myocardial Infarction (STEMI), Extensive (Large) ST-Elevation Myocardial Infarction (STEMI)

2) By Non-ST-Elevation Myocardial Infarction (NSTEMI): Subendocardial Non-ST-Elevation Myocardial Infarction (NSTEMI), Multi-Vessel Non-ST-Elevation Myocardial Infarction (NSTEMI), Silent Non-ST-Elevation Myocardial Infarction (NSTEMI), Recurrent Non-ST-Elevation Myocardial Infarction (NSTEMI)

Which Trends Are Contributing To Changes In The Acute Myocardial Infarction Market?

Key players within the acute myocardial infarction market are prioritizing securing regulatory clearances to broaden their product offerings, improve the effectiveness of treatments, and solidify their standing in the market. These approvals signify formal permissions granted by health authorities like the FDA and EMA, which certify that pharmaceutical products and medical equipment fulfill criteria for safety, effectiveness, and quality prior to being introduced to the market. An example is Sungen Biomedical, a biopharmaceutical firm from China, which in March 2025, was granted FDA Fast Track Designation for its monoclonal antibody drug, SGC001. This drug is notable as the first globally developed for the urgent management of acute myocardial infarction (AMI). The designation acknowledges SGC001’s capability to diminish cardiomyocyte apoptosis and enhance circulation in areas affected by ischemia. Given encouraging preclinical outcomes that suggest improvements in recovery and a reduction in mortality rates, the Fast Track status facilitates faster communication with the FDA, thereby speeding up the approval process and allowing patients more rapid access to this novel AMI treatment.

Who Are The Companies Competing Within The Acute Myocardial Infarction Market?

Major companies operating in the acute myocardial infarction market are Johnson & Johnson, F Hoffmann La Roche AG, Merck & Co Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Siemens Healthineers, Koninklijke Philips NV, Boston Scientific Corporation, Daiichi Sankyo Company Limited, Terumo Corporation, MicroPort Scientific Corporation, Pfizer Inc, Boehringer Ingelheim International GmbH, Amgen Inc

Get The Full Acute Myocardial Infarction Market Report:

https://www.thebusinessresearchcompany.com/report/acute-myocardial-infarction-global-market-report

Which Region Leads The Acute Myocardial Infarction Market In Terms Of Market Share?

North America was the largest region in the acute myocardial infarction market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute myocardial infarction market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Acute Myocardial Infarction Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/acute-myocardial-infarction-global-market-report

Browse Through More Reports Similar to the Global Acute Myocardial Infarction Market 2026, By The Business Research Company

Coronary Artery Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/coronary-artery-disease-global-market-report

Acute Coronary Syndrome Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

Myocardial Ischemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/myocardial-ischemia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795